The Ahmedabad-based Senores Pharmaceuticals specializes in developing and manufacturing pharmaceutical products for regulated markets in the US, Canada, and the UK, while also serving emerging markets. The IPO attracted significant investor attention, reflecting confidence in the company’s growth potential and robust business model.
Key IPO Details
- Issue Period: December 20–24, 2024
- Price Band: ₹372–₹391 per share
- Lot Size: 38 shares
- Total Issue Size: ₹582.11 crore
- Fresh Issue: ₹500 crore
- Offer for Sale (OFS): 21,00,000 equity shares
Subscription Status
The IPO was oversubscribed 93.41 times, with strong demand across all categories:
- Qualified Institutional Bidders (QIBs): 94.66 times
- Non-Institutional Investors (NIIs): 96.11 times
- Retail Investors: 89.23 times
- Employees: 19.92 times
Allotment Status
The allotment of shares for Senores Pharmaceuticals is scheduled to be finalized on Thursday, December 26, 2024. Notifications for fund debits or revocation of IPO mandates will be sent by Friday, December 27, 2024.
How to Check Allotment Status
On BSE Website:
- Visit BSE Allotment Status.
- Select Equity under the issue type.
- Choose Senores Pharmaceuticals Limited from the dropdown menu.
- Enter your Application Number and PAN ID.
- Verify the captcha and click on Search.
On Link Intime Portal:
- Go to Link Intime Allotment Portal.
- Select Senores Pharmaceuticals from the dropdown (if finalized).
- Choose one mode: Application Number, Demat Account Number, or PAN ID.
- Select application type: ASBA or Non-ASBA.
- Enter the required details and captcha, then click Submit.
Grey Market Premium (GMP)
- Current GMP: ₹240 per share
- Expected Listing Pop: Up to 60%
The steady GMP reflects strong investor confidence, suggesting a potential listing price of ₹631 (₹391 issue price + ₹240 GMP).
Business Highlights
- Incorporated: December 2017
- Therapeutic Focus: Antibiotics, anti-fungal treatments, and more.
- Portfolio: 55 products as of September 30, 2024.
- Markets: Primarily US, Canada, UK, and emerging markets.
Listing Date and Lead Managers
- Listing Date (Tentative): Monday, December 30, 2024
- Exchanges: NSE and BSE
- Lead Managers:
- Equirus Capital
- Ambit
- Nuvama Wealth Management
Key Takeaways
- The IPO’s overwhelming subscription and steady GMP indicate strong investor confidence.
- Senores Pharmaceuticals’ established presence in regulated markets and growing portfolio position it for long-term growth.
- Investors can expect a robust listing, supported by solid fundamentals and favorable market sentiment.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investors should perform due diligence or consult a financial advisor before making investment decisions.
Click here to know more.
